MoonLake Immunotherapeutics

NasdaqCM:MLTX Stock Report

Market Cap: US$1.4b

MoonLake Immunotherapeutics Management

Management criteria checks 3/4

MoonLake Immunotherapeutics' CEO is Jorge da Silva, appointed in Jul 2021, has a tenure of 4.83 years. total yearly compensation is $4.94M, comprised of 15.4% salary and 84.6% bonuses, including company stock and options. directly owns 4.01% of the company’s shares, worth $54.64M. The average tenure of the management team and the board of directors is 2.9 years and 4.1 years respectively.

Key information

Jorge da Silva

Chief executive officer

US$4.9m

Total compensation

CEO salary percentage15.42%
CEO tenure4.8yrs
CEO ownership4.0%
Management average tenure2.9yrs
Board average tenure4.1yrs

Recent management updates

Recent updates

Analysis Article • Jul 26

Is MoonLake Immunotherapeutics (NASDAQ:MLTX) Using Debt In A Risky Way?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • Jun 03

MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest

Summary MoonLake Immunotherapeutics completed enrollment in the two-phase 3 VELA studies using Sonelokimab for the treatment of patients with hidradenitis suppurativa. The global psoriatic arthritis market is projected to reach $24.2 billion by the end of 2031. Merck's $3 billion non-binding acquisition offer highlights the significant buyout potential of the company and validates its late-stage pipeline value. MLTX's strong cash position funds operations into 2028, but risks remain around clinical trial outcomes and competitive benchmarks, especially versus SKYRIZI in PsA. Read the full article on Seeking Alpha
Analysis Article • Apr 09

We Think MoonLake Immunotherapeutics (NASDAQ:MLTX) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Apr 08

MoonLake Immunotherapeutics: A Buy At Dips

Summary MoonLake Immunotherapeutics showed strong performance with sonelokimab, outperforming competitors in clinical trials, yet faced a significant stock drop due to institutional sell-offs. Despite mixed results from the ARGO study, sonelokimab demonstrated superior efficacy against Humira and Secukinumab, indicating strong potential for future success. Institutional sell-offs in late 2023 caused a drastic stock decline, but MLTX remains financially stable with a cash runway extending into 2027. With promising catalysts in 2025 and potential market opportunities worth billions, MLTX is a buy on dips for risk-tolerant investors. Read the full article on Seeking Alpha
Analysis Article • Jan 20

Are Investors Undervaluing MoonLake Immunotherapeutics (NASDAQ:MLTX) By 39%?

Key Insights Using the 2 Stage Free Cash Flow to Equity, MoonLake Immunotherapeutics fair value estimate is US$72.37...
Analysis Article • Dec 16

We're Not Very Worried About MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Oct 13

MoonLake Immunotherapeutics: Lack Of Near Term Catalysts Makes It A Hold

Summary MoonLake Immunotherapeutics' stock has been volatile but is currently back to its previous year's level, reflecting mixed performance in a bullish biotech market. SLK, MoonLake's key asset, shows promising Phase 2b results in HS, PsA, and psoriasis, with Phase 3 trials ongoing and new indications being explored. Financially, MLTX has a $3bn market cap and $520mn cash, ensuring a runway of 10-12 quarters despite significant R&D expenses. The primary risk is the lack of near-term catalysts, with significant data expected only by mid-2025, making it a hold rather than a buy. Read the full article on Seeking Alpha
Analysis Article • Aug 27

MoonLake Immunotherapeutics (NASDAQ:MLTX) Is In A Strong Position To Grow Its Business

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Jul 18

MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward

Summary MoonLake Immunotherapeutics launched VELA-1 and VELA-2 as two studies using sonelokimab for the treatment of patients with Hidradenitis Suppurativa; Topline 16-week primary endpoint expected end of 2026. The global hidradenitis suppurativa market is expected to reach $1 billion by 2029. The initiation of the IZAR program, using sonelokimab for patients with Psoriatic Arthritis, is expected to launch in Q4 of 2024; Primary endpoint data is expected at the end of 2026. There is potential to establish a competitive advantage by using Nanobody technology, which incorporates smaller molecules along with drugs developed to target both cytokines IL-17A and IL-17F. Read the full article on Seeking Alpha
Analysis Article • May 14

Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Feb 26

MoonLake Immunotherapeutics: Novel Technology, But Still In Phase 3

Summary MoonLake Immunotherapeutics has exclusively licensed nanobody technology to develop treatments for inflammatory diseases. The company is focusing on psoriasis and hidradenitis suppurativa, targeting interleukins 17A and 17F as the main culprits for excessive inflammation. MoonLake has completed phase 2 clinical trials and is entering phase 3, showing promising results so far, but there are still development risks and outstanding financial burdens. The value gap exists, which is positive, but with the development risks of a novel technology, we aren't sure what sort of margin of safety can be expected. Read the full article on Seeking Alpha
Analysis Article • Jan 29

We're Not Worried About MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Oct 16

Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, MoonLake...
Seeking Alpha • Jul 26

Vetter Pharma to provide fill and finish services to MoonLake Immunotherapeutics

MoonLake Immunotherapeutics (NASDAQ:MLTX) on Tuesday said it had signed a services agreement with contract development and manufacturing organization Vetter Pharma International GmbH. As per the deal, Vetter will be responsible for fill and finish services. Vetter will oversee the the aseptic filling of syringes with MLTX's investigational nanobody sonelokimab. Vetter will also be responsible for the subsequent assembly into an autoinjector combination device and packaging. MLTX stock -1.8% to $6.93 in morning trading.

CEO Compensation Analysis

How has Jorge da Silva's remuneration changed compared to MoonLake Immunotherapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025US$5mUS$762k

-US$227m

Sep 30 2025n/an/a

-US$210m

Jun 30 2025n/an/a

-US$176m

Mar 31 2025n/an/a

-US$145m

Dec 31 2024US$1mUS$698k

-US$119m

Sep 30 2024n/an/a

-US$81m

Jun 30 2024n/an/a

-US$55m

Mar 31 2024n/an/a

-US$41m

Dec 31 2023US$1mUS$586k

-US$36m

Sep 30 2023n/an/a

-US$46m

Jun 30 2023n/an/a

-US$46m

Mar 31 2023n/an/a

-US$48m

Dec 31 2022US$4mUS$460k

-US$50m

Sep 30 2022n/an/a

-US$58m

Jun 30 2022n/an/a

-US$54m

Dec 31 2021US$5mUS$230k

-US$64m

Compensation vs Market: Jorge's total compensation ($USD4.94M) is about average for companies of similar size in the US market ($USD5.37M).

Compensation vs Earnings: Jorge's compensation has increased whilst the company is unprofitable.

CEO

Jorge da Silva (48 yo)

4.8yrs
Tenure
US$4,943,209
Compensation

Dr. Jorge Santos da Silva, Ph D., is a Co-Founder of MoonLake Immunotherapeutics (Alternate name MoonLake Immunotherapeutics AG) and has served as the Chief Executive Officer since April 2022 and serves as...

Leadership Team

NamePositionTenureCompensationOwnership
Jorge da Silva
Co-Founder4.8yrsUS$4.94m4.01%
$ 54.6m
Kristian Reich
Co-Founder & Chief Scientific Officer4.1yrsUS$4.80m4.13%
$ 56.2m
Matthias Bodenstedt
Chief Financial Officer4.1yrsUS$4.69m1.61%
$ 21.9m
Oliver Daltrop
Chief Technical Officerno datano datano data
Carla Bretes
Director of Investor Relations & External Communications2.3yrsno datano data
Nicolas Mosimann
General Counsel3.4yrsno datano data
Joana Cortez
Associate Vice-President of Legal & Compliance2.3yrsno datano data
Tino Anthamatten
Vice President of Marketing2.3yrsno datano data
Luciana Marques
Associate Vice-President of HR2.3yrsno datano data
Nuala Brennan
Chief Clinical Development Officer4.7yrsno datano data
Roman Akbar-Haase
Chief of Staff to the Executive Board2.3yrsno datano data
Wulf Boecher
Chief Medical Officerno datano datano data
2.9yrs
Average Tenure
48yo
Average Age

Experienced Management: MLTX's management team is considered experienced (2.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jorge da Silva
Co-Founder4.1yrsUS$4.94m4.01%
$ 54.6m
Catherine Moukheibir
Independent Director4.1yrsUS$286.85k0%
$ 0
Andrew Phillips
Independent Director4.1yrsUS$280.35k0%
$ 0
Ramnik Xavier
Independent Director4.1yrsUS$299.35k0%
$ 0
Spike Loy
Lead Independent Director4.1yrsUS$276.85k0%
$ 0
4.1yrs
Average Tenure
53yo
Average Age

Experienced Board: MLTX's board of directors are considered experienced (4.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/29 21:55
End of Day Share Price 2026/05/29 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

MoonLake Immunotherapeutics is covered by 16 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Julian HarrisonBTIG
Prakhar AgrawalCantor Fitzgerald & Co.
Samantha Lynn SemenkowCitigroup Inc